Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wellgistics Health, Inc. (WGRX)
USD2.97
+0.04 (+1.37%)
US NASDAQ Healthcare Medical - Distribution
Address
3000 Bayport Drive 33607
Tampa, FL, US
Tampa, FL, US
CEO
Prashant Patel
Website
wellgisticshealth.com
IPO
2025-02-25
CIK 2030763 ISIN US9495032057
Description
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a variety of generic and brand-name pharmaceuticals, alongside over-the-counter healthcare and consumer merchandise. The company also delivers a suite of third-party logistics (3PL) services, encompassing warehousing, inventory control, pick-and-pack operations, and shipping solutions, specifically designed for small to mid-sized pharmaceutical producers. Furthermore, Wellgistics manages the DelivMeds platform, an integrated pharmaceutical hub that streamlines prescription transfers and offers essential backend clinical concierge support to its network of independent pharmacies. It also runs a specialized retail community service. Established in 2022 and headquartered in Tampa, Florida, the organization adopted its current name, Wellgistics Health, Inc., in October 2024, having previously operated as Danam Health, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.97
+0.04 (+1.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
757.2K
Beta
-1.46
Float Shares
12.58M
Free Float %
17.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.45% | +103.14% | +16.67% | -34.45% | -70.98% | -57.95% | -93.73% | -95.59% | -95.59% | -95.59% | -95.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.97
Quality scores
Altman Z-Score
-12.19
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%+28.7% ★ Q1'26: -85.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-1,000.0% Q1'26: +88.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-317.4% Q1'26: -218.9% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-347.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-671.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+36.7% Q1'26: +101.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-0.32× Q1'26: -1.27× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.64M
OE per share TTM
-0.16
Owner's Yield
-60.52%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NORTHERN TRUST CORP | 74.1K +— (+0.0%) | 7.1K -22.4K (-75.9%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD0.87 -88.5% | 3 qtrs — |
| 2 | ACT ADVISORS, LLC. | 35.4K +35.4K (+100.0%) | 3.4K +3.4K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.002 pp | USD0.10 +0.0% | 1 qtrs NEW |
| 3 | AQR CAPITAL MANAGEMENT LLC | 20.3K +20.3K (+100.0%) | 2.0K +2.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD0.10 +0.0% | 1 qtrs NEW |
| 4 | VIRTU FINANCIAL LLC | — -44.8K (-100.0%) | — -18.0K (-100.0%) | 0.00% -0.063 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 30.3K | 0.05% |
| 2 | Vanguard Total Stock Market ETF VTI | 0.00% | 6.9K | 0.03% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 14.64 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 40.20 | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 2.97 | 0.17% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 15.49 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 8.16 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 3.20 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 0.39 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.05 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Patel Prashant | Director / Officer | A-Award | A | Warrant | 5,000,000 | 0.01 | 50.0K | 5,000,000 | D | ↗ |
| 2026-03-31 | AJJARAPU SURENDRA K | Director | A-Award | A | Warrant | 5,000,000 | 0.01 | 50.0K | 5,000,000 | D | ↗ |
| 2026-03-19 | Velez Marlene | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-02-04 | Herman Gary L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-07 | Sherb Eric Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-02 | Lee Steven Dale | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-02 | Fell Donald G. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-02 | Doss Howard A. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-02 | PETERSON MICHAEL L | Director | A-Award | D | Common Stock | 200,000 | 0.90 | 180.0K | 200,000 | D | ↗ |
| 2025-04-10 | PETERSON MICHAEL L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-26.2K
Shares Outstanding
70.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shafaat Pirani | Chief Clinical Officer | 275.0K | — |
| Srini Kalla | Chief Technology Officer | 233.2K | male |
| Eric Michael Sherb | Interim-CFO | 182.0K | male |
| Prashant Patel | Interim-CEO, President & Director | 13.4K | male |
| Nikul Panchal | Chief Pharmacy Officer | — | male |
| Gerald E. Commissiong | Chief Business Officer | — | male |
| Ari Aichbhaumik | Senior Vice President of Supply Chain | — | male |
ESG Rating
ESG Score History MEDICAL - DISTRIBUTION
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WGRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
